Cancer - Discovery Chemistry, PGRD La Jolla Laboratories, Pfizer, Inc., San Diego, CA 92121, USA.
Expert Opin Ther Pat. 2006 May;16(5):713-8. doi: 10.1517/13543776.16.5.713.
Amgen disclosed a series of 4-heteroaryloxy quinoline/quinazoline compounds as multiple kinase inhibitors, including hepatocyte growth factor (HGF) receptor tyrosine kinase c-Met and vascular endothelial growth factor (VEGF) receptor tyrosine kinase. These compounds are stated to have wide therapeutic applications for the treatment of a variety of cancers, hypertension, arteriosclerosis, myocardial infarction and rheumatoid arthritis.
安进公司披露了一系列 4-杂芳氧基喹啉/喹唑啉类化合物作为多激酶抑制剂，包括肝细胞生长因子（HGF）受体酪氨酸激酶 c-Met 和血管内皮生长因子（VEGF）受体酪氨酸激酶。这些化合物据称具有广泛的治疗应用，可用于治疗多种癌症、高血压、动脉硬化、心肌梗塞和类风湿性关节炎。
